Mzzchj4ftw2vrygvha3j 2017 06 29 11 10 50

ACT Genomics

ic No Reviews Yet
ic No Completed Orders
Taipei, TW

About ACT Genomics

We are the world's leading cancer solution provider. Based in Taiwan, we also provide effective services through our offices in Singapore, Hong Kong, Shanghai and Tokyo. Joint by experts from the field of cancer biology, cancer genomics and bioinformatics, we provide optimal cancer treatment plan, cancer... Show more »

We are the world's leading cancer solution provider. Based in Taiwan, we also provide effective services through our offices in Singapore, Hong Kong, Shanghai and Tokyo. Joint by experts from the field of cancer biology, cancer genomics and bioinformatics, we provide optimal cancer treatment plan, cancer relapse and drug resistance monitoring as well as cancer risk assessment and immunotherapy evaluation. We are dedicated to provide every cancer patient personalized genomic information based-treatment plans through our cutting-edge Next Generation Sequencing (NGS) platform, medical report and integrated services.

Show less

Our Services (4)


ic

Neoantigen Prediction

Price on request

Neoantigen Ranking System and Service

The neoantigen identification process consists of conducting whole exome sequencing (WES) for tumor-normal-paired samples, detecting somatic nonsynonymous mutations, identifying mutated epitope, typing the HLA of the sample, and neoantigen ranking using artificial intelligence, biology... Show more »

Neoantigen Ranking System and Service

The neoantigen identification process consists of conducting whole exome sequencing (WES) for tumor-normal-paired samples, detecting somatic nonsynonymous mutations, identifying mutated epitope, typing the HLA of the sample, and neoantigen ranking using artificial intelligence, biology knowledge, and manual curation. A list of peptide which likely to elicits immune response will be provided.

Sample type:
1. FFPE tumor tissue sample (with >30% tumor purity), AND
2. PBMC sample

Turn-around Time:
45 calendar days after receiving qualified samples

Show less

ic

Drug Development

Price on request

Under our CAP-accredited next generation sequencing laboratory, along with an experienced in-house bioinformatics team, ACT Genomics understands the challenges faced by pharmaceuticals today and is confident to provide services to accelerate the process of oncology drug development by identify biomarker for targeted therapies,... Show more »

Under our CAP-accredited next generation sequencing laboratory, along with an experienced in-house bioinformatics team, ACT Genomics understands the challenges faced by pharmaceuticals today and is confident to provide services to accelerate the process of oncology drug development by identify biomarker for targeted therapies, immune checkpoint inhibitors (tumor mutational burden) and companion diagnostic (CDx).

With the superior sensitivity and have a quick turn-around time, ACT Genomics is devoted to providing clinical-grade, reliable results for drug development. Our current biopharma projects include:
- Investigational assay development
- Biomarker identification
- Patient stratification
- Comprehensive cancer molecular analysis
- Consultation

Show less
solid tumor cancer Cancer solid tumor Next Generation Sequencing Bioinformatics Show 6 more tags Show less

ic

Neoantigen Identification

Price on request

Neoantigen Ranking System and Service

The neoantigen identification process consists of conducting whole exome sequencing (WES) for tumor-normal-paired samples, detecting somatic nonsynonymous mutations, identifying mutated epitope, typing the HLA of the sample, and neoantigen ranking using artificial intelligence, biology... Show more »

Neoantigen Ranking System and Service

The neoantigen identification process consists of conducting whole exome sequencing (WES) for tumor-normal-paired samples, detecting somatic nonsynonymous mutations, identifying mutated epitope, typing the HLA of the sample, and neoantigen ranking using artificial intelligence, biology knowledge, and manual curation. A list of peptide which likely to elicits immune response will be provided.

Sample type:
1. FFPE tumor tissue sample (with >30% tumor purity), AND
2. PBMC sample

Turn-around Time:
45 calendar days after receiving qualified samples

Show less
solid tumor cancer Cancer solid tumor Next Generation Sequencing Whole Exome Sequencing Bioinformatics FFPE tissue Blood Show 9 more tags Show less

ic

RNA-Based Immune Profiling Assay

Price on request

Tumor Microenvironment Gene Expression Profiling (ACT_TME)

ACT_TME is an RNA-based immune profiling assay that enables the characterization of tumor-immune microenvironment beyond traditional “immune-filtrated” or “non-immune-filtrated” classification, providing insights to facilitate immune-oncology drug development.

1.... Show more »

Tumor Microenvironment Gene Expression Profiling (ACT_TME)

ACT_TME is an RNA-based immune profiling assay that enables the characterization of tumor-immune microenvironment beyond traditional “immune-filtrated” or “non-immune-filtrated” classification, providing insights to facilitate immune-oncology drug development.

  1. Profiles > 90 cancer genes to evaluate immunotherapy
  2. Proprietary chip-based multiplex qPCR platform
  3. Fast turnaround time
  4. Accommodates highly degraded specimens with low inputs

Sample Type:
1. FFPE tumor tissue sample
2. Total RNA
3. Fragmented RNA
4. Cell lysates

Time to Result:
3 hrs

Show less
solid tumor cancer Cancer solid tumor mutiplex qPCR FFPE tissue Show 6 more tags Show less

Not finding what you're looking for?

Get info on this provider's capabilities without requesting a quote.

ACT Genomics has not received any reviews.

ACT Genomics has not received any endorsements.